- Home
- HAIN vs KLRS Comparison
HAIN vs KLRS Comparison
Compare HAIN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAIN
- KLRS
- Stock Information
- Founded
- HAIN 1993
- KLRS 2019
- Country
- HAIN United States
- KLRS United States
- Employees
- HAIN N/A
- KLRS N/A
- Industry
- HAIN Packaged Foods
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAIN Consumer Staples
- KLRS Health Care
- Exchange
- HAIN Nasdaq
- KLRS Nasdaq
- Market Cap
- HAIN 146.2M
- KLRS 129.0M
- IPO Year
- HAIN 1993
- KLRS N/A
- Fundamental
- Price
- HAIN $1.66
- KLRS $2.50
- Analyst Decision
- HAIN Hold
- KLRS Buy
- Analyst Count
- HAIN 9
- KLRS 1
- Target Price
- HAIN $3.91
- KLRS N/A
- AVG Volume (30 Days)
- HAIN 1.5M
- KLRS 39.9K
- Earning Date
- HAIN 08-26-2025
- KLRS 08-15-2025
- Dividend Yield
- HAIN N/A
- KLRS N/A
- EPS Growth
- HAIN N/A
- KLRS N/A
- EPS
- HAIN N/A
- KLRS N/A
- Revenue
- HAIN $1,615,231,000.00
- KLRS N/A
- Revenue This Year
- HAIN N/A
- KLRS N/A
- Revenue Next Year
- HAIN N/A
- KLRS N/A
- P/E Ratio
- HAIN N/A
- KLRS N/A
- Revenue Growth
- HAIN N/A
- KLRS N/A
- 52 Week Low
- HAIN $1.30
- KLRS $2.28
- 52 Week High
- HAIN $9.43
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- HAIN 43.73
- KLRS N/A
- Support Level
- HAIN $1.46
- KLRS N/A
- Resistance Level
- HAIN $1.77
- KLRS N/A
- Average True Range (ATR)
- HAIN 0.11
- KLRS 0.00
- MACD
- HAIN 0.03
- KLRS 0.00
- Stochastic Oscillator
- HAIN 59.68
- KLRS 0.00
About HAIN Hain Celestial Group Inc. (The)
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.